Nanoligent, a biotechnology company specializing in targeted nanomedicines for cancer, has raised €12 million in funding led by Inveready to advance its lead compound NNL1524 into clinical trials while enhancing production capabilities.

Information on the Target

Nanoligent is a biotechnology company focused on the development of targeted nanomedicines for cancer treatment. Recently, the company successfully raised €12 million in a funding round led by Inveready through its Inveready Biotech IV fund. Additional participants included CDTI (via its Innvierte program), Clave Capital through its Clave Innohealth fund, and existing investors such as i&i Biotech Fund I, Italian Angels for Growth, and Avanteca.

This capital injection will enable Nanoligent to complete the regulatory preclinical development of its lead compound, NNL1524, and advance into clinical trials with a Phase Ia study involving patients with solid tumors. Furthermore, the funding will support an increase in production capacity and optimization of manufacturing processes.

Industry Overview in the Target’s Specific Country

Spain has seen significant developments in the biotechnology sector, particularly in oncology, where innovative therapies are urgently needed due to the high incidence of cancer. The l